Summary
- Profile Type
- Technology offer
- POD Reference
- TODE20240207027
- Term of Validity
- 7 February 2024 - 6 February 2026
- Company's Country
- Germany
- Type of partnership
- Commercial agreement with technical assistance
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A German university offers a new method for expression of a transgene of interest from neural precursor cells. This can be applied in research and therapy. Advantages include lower costs, easier handling and more effectiveness. Licensees are sought
- Full Description
-
Human pluripotent stem cells (hPSCs; including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) provide unlimited opportunities for biomedical research and therapeutic applications. One of the key promises of stem cell technologies is the in vitro production of bulk quantities of specific human cell types with bona fide properties for biomedical research or therapeutic interventions.
The present invention of a German university relates to a method for expression of a transgene of interest from neural precursor cells (NPCs) comprising the steps of: a) Providing neural precursor cells; b1) i) targeted insertion of a nucleotide sequence encoding a transcriptional regulator protein being under the control of a suitable promoter into a first genomic location; and ii) targeted insertion of a nucleotide sequence encoding a transgene of interest into a second genomic location, wherein the transgene of interest is operably linked to a suitable promoter, which is regulated by the transcriptional regulator protein; or b2) targeted insertion of the nucleotide sequence encoding a transgene of interest into a genomic location, wherein the transgene of interest is operably linked to a constitutive promoter, and c) expression of the transgene of interest. Further is provided a system for expression of a transgene of interest from neural precursor cells. Additionally, the present invention is directed to a method for expression of a transgene of interest from stem cells.
The inventors have developed a GSH-targeted controllable transcription system to smNPCs and utilized this for efficient constitutive or inducible reporter expression and for rapid and deterministic programming of smNPCs into, e.g., cortical neurons.
The university offers license agreements. - Advantages and Innovations
- Due to the lower costs of cell cultivation, the easier handling of the cell cultures, the effectiveness of the resources of the hNPC cultures, the faster maturation kinetics of the desired target cells, the advantages with regard to the targeted GSH integration of the transgenes and the new possibility for expression of multiple (e.g. more than 2) transgenes in stem cells, the present invention can very well overcome the existing disadvantages of the prior art
- Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
Partner Sought
- Expected Role of a Partner
- The university offers license agreements to providers of research tools. The partner should produce and sell the invention.
- Type and Size of Partner
- SME 11-49
- SME 50 - 249
- Big company
- Type of partnership
- Commercial agreement with technical assistance
Dissemination
- Technology keywords
- 06001002 - Clinical Research, Trials
- 06001012 - Medical Research
- Market keywords
- 05004004 - Medical instruments
- 05007007 - Other medical/health related (not elsewhere classified)
- 05003006 - Other therapeutic (including defibrillators)
- Sector Groups Involved
- Health
- Targeted countries
- All countries
